INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering
Portfolio Pulse from Benzinga Newsdesk
INmune Bio, Inc. (NASDAQ:INMB) has announced a registered direct offering, raising approximately $4.8 million in gross proceeds. The offering involves the sale of 571,592 shares of common stock at $8.32 per share, with warrants exercisable at $9.152, a 10% premium. Officers, employees, and directors purchased about 20% of the offering. The proceeds will fund Phase 2 trials for Alzheimer's and prostate cancer treatments. The offering is expected to close on April 24, 2024.
April 22, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio, Inc. raises $4.8M through a direct offering, with proceeds aimed at funding critical Phase 2 trials for Alzheimer's and prostate cancer.
The successful capital raise of approximately $4.8 million for INmune Bio, Inc. indicates strong internal support, with officers, employees, and directors purchasing about 20% of the offering. This influx of funds is earmarked for advancing the company's Phase 2 trials in Alzheimer's and prostate cancer, which could significantly impact the company's valuation and investor interest if these trials yield positive results. The offering's structure, with warrants exercisable at a 10% premium, also suggests confidence in the company's future stock performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100